glp 1 kidney stones A Rise in in GLP-1 Users and Those with Metabolic Syndrome The boom in GLP1 drugs

10.1038/s41598-018-23408-0 2 Alarcn-VeleiroC.Mato-BasaloR.Lucio-GallegoS.Vidal-PampnA.Quinds-VarelaM.Al-QatarnehT.et al (2023)

doi: 10.1002/dmrr.2810 34 PratleyREArodaVRLingvayILdemannJAndreassenCNavarriaAet al

We believe that it is reasonable to require an enhanced disclosure to the patient who may be prescribed one of these drugs that this molecule is not as well-characterized as drugs that would normally be dispensed to patients, and the patient needs to understand that there may be a higher risk profile, and they should only be taken under the care of a physician, he said

Published preclinical data in rodents suggests doses equivalent to 200mg+ in humans produce off-target effects on folate metabolism and S-adenosylmethionine (SAMe) pools

The results showed that quercetin supplementation significantly attenuated the strength loss compared to a placebo

It takes time. Tirzepatide, the newer entrant, is not being shown to be worse for the heart than semaglutide